Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs

References

• European Association for The Study of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis. Br. J. Hepatol.50(2), 227–242 (2009).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH et al. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int.2, 538–549 (2008).
   Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology50(3), 661–662 (2009).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol.48(2), 335–352 (2008).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology21(1), 77–82 (1995).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology26(5), 1338–1342 (1997).
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol.45(4), 529–538 (2006).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295(1), 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology130(3), 678–686 (2006).
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Jen CL et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin. Gastroenterol. Hepatol.5(8), 921–931 (2007).
   PubMed Web of Science ®Google Scholar
• Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol.101(8), 1797–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J. Gastroenterol. Hepatol.19(6), 670–675 (2004).
   PubMed Web of Science ®Google Scholar
• Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl Cancer Inst.97(4), 265–272 (2005).
   PubMed Web of Science ®Google Scholar
• Yuan HJ, Yuen MF, Ka-Ho WD, Sablon E, Lai CL. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J. Viral Hepatol.12(4), 373–379 (2005).
   PubMed Web of Science ®Google Scholar
• Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology37(6), 1309–1319 (2003).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351(15), 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest.115(2), 209–218 (2005).
   PubMed Web of Science ®Google Scholar
• Friedman SL. Liver fibrosis – from bench to bedside. J. Hepatol.38(Suppl. 1), S38–S53 (2003).
   PubMed Web of Science ®Google Scholar
• Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology134(6), 1655–1669 (2008).
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology24(2), 289–293 (1996).
   PubMed Web of Science ®Google Scholar
• Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J. Hepatol.47(4), 598–607 (2007).
   PubMed Web of Science ®Google Scholar
• Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology1(5), 431–435 (1981).
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol.22(6), 696–699 (1995).
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Burroughs AK, Standish R et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology49(4), 1236–1244 (2009).
   PubMed Web of Science ®Google Scholar
• Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology45(4), 886–894 (2007).
   PubMed Web of Science ®Google Scholar
• McHutchison J, Goodman Z, Patel K et al. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology138(4), 1365–1373 (2010).
   PubMed Web of Science ®Google Scholar
• Manousou P, Dhillon AP, Isgro G et al. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl.17(2), 178–188 (2011).
   PubMed Web of Science ®Google Scholar
• Boursier J, de Ledinghen V, Zarski JP et al. A new combination of blood test and fibroscan for accurate noninvasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am. J. Gastroenterol.106(7), 1255–1263 (2011).
   PubMed Web of Science ®Google Scholar
• Guechot J, Lasnier E, Sturm N, Paris A, Zarski JP. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin. Chim. Acta411(1–2), 86–91 (2010).
   PubMed Web of Science ®Google Scholar
• Cales P, Boursier J, Oberti F et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol. Clin. Biol.32(6 Suppl. 1), 40–51 (2008).
   PubMedGoogle Scholar
• Smith JO, Sterling RK. Systematic review: noninvasive methods of fibrosis analysis in chronic hepatitis C. Aliment. Pharmacol. Ther.30(6), 557–576 (2009).
   PubMed Web of Science ®Google Scholar
• Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology39(6), 1647–1654 (2004).
   PubMed Web of Science ®Google Scholar
• Falize L, Guillygomarc’h A, Perrin M et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology44(2), 472–477 (2006).
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology122(5), 1303–1313 (2002).
   PubMed Web of Science ®Google Scholar
• Maylin S, Martinot-Peignoux M, Moucari R et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology135(3), 821–829 (2008).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med.341(17), 1256–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med.339(2), 61–68 (1998).
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology29(3), 889–896 (1999).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology124(1), 105–117 (2003).
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Tassopoulos NC, Goldin RD et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis. Br. J. Hepatol.42(2), 173–179 (2005).
   PubMedGoogle Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovirdipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med.348(9), 800–807 (2003).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Adefovirdipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med.348(9), 808–816 (2003).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovirdipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology48(3), 750–758 (2008).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovirdipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology131(6), 1743–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med.357(25), 2576–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Hou J, Xu D, Shi G et al. Five-year telbivudine treatment with effective viral suppression results in resolution of liver inflammation and fibrosis regression in patients with chonic hepatitis B. J. Hepatol.54, S287 (2011).
   Google Scholar
• Liaw YF, Gane E, Leung N et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology136(2), 486–495 (2009).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Gane E, Liaw YF et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis. Br. J. Hepatol.51(1), 11–20 (2009).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology40(4), 883–891 (2004).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Di Stefano R, Ferraro D et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir. Ther.10(3), 431–439 (2005).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Seto WK, Chow DH et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther.12(8), 1295–1303 (2007).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Pokornoski KA, Rose RE et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J. Hepatol.50(Suppl. 1), S10 (2009).
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.354(10), 1001–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.354(10), 1011–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Raptopoulou-Gigi M, Cheinquer H et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology54(1), 91–100 (2011).
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Kew YS et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology51(2), 422–430 (2010).
   PubMed Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology52(3), 886–893 (2010).
   PubMed Web of Science ®Google Scholar
• Schiff E, Lee SS, Chao YC et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol.9, 274–276 (2011).
   PubMed Web of Science ®Google Scholar
• Yokosuka O, Takaguchi K, Fujioka S et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J. Hepatol.52(6), 791–799 (2010).
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Marcellin P, Buti M et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology140(1), 132–143 (2011).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med.359(23), 2442–2455 (2008).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Gane EJ et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology54(Suppl. 1), Abstract 1375 (2011).
   PubMedGoogle Scholar
• Boyd A, Lasnier E, Molina JM et al. Liver fibrosis changes in HIV–HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir. Ther.15(7), 963–974 (2010).
   PubMed Web of Science ®Google Scholar
• Boursier J, Bacq Y, Halfon P et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur. J. Gastroenterol. Hepatol.21(1), 28–38 (2009).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sheen IS, Lee CM et al. Tenofovirdisoproxilfumarate (TDF), entracitabine/TDF, ndentecavirin patients with decompensated chronic hepatitis B liver disease. Hepatology53(1), 62–72 (2011).
   PubMed Web of Science ®Google Scholar
• Manolakopoulos S, Triantos C, Theodoropoulos J et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J. Hepatol.51(3), 468–474 (2009).
   PubMed Web of Science ®Google Scholar
• Pozzi M, Pizzala DP, Maldini FF, Doretti A, Ratti L. Portal pressure reduction after entecavir treatment in compensated HBV cirrhosis. Hepatogastroenterology56(89), 231–235 (2009).
   PubMedGoogle Scholar